RAPT THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.33 USD | +2.52% |
|
+2.84% | -66.48% |
Chart calendar RAPT Therapeutics, Inc.
71c5ad10664b8bedf81b3e744730d.nLt8m36Is0HueldoZN7XxqpTdhlFfl_9tQrK1QK6u3w.w9oR6jTvwzjXNHonJem1lsEJPFIkKyeP0ECinDrXiQrx4izUD-GBA4RCGg~67a47d784b4739864e256c387a67455b
Upcoming events on RAPT Therapeutics, Inc.
Past events on RAPT Therapeutics, Inc.
| 09/04/2024 09:30 pm | American Association for Cancer Research Meeting - Abstract Number : CT226 |
| 09/04/2024 02:00 am | American Association for Cancer Research Meeting - Abstract Number : 2654 |
| 08/04/2024 09:30 pm | American Association for Cancer Research Meeting - Abstract Number : 2485 |
| 07/03/2024 06:30 pm | Q4 2023 Earnings Release |
| 20/02/2024 07:00 pm | Business Update Call |
| 08/02/2024 12:30 am | Guggenheim Healthcare Talks Biotechnology Conference |
| 10/01/2024 10:30 pm | JPMorgan Healthcare Conference |
| 30/11/2023 01:05 am | Evercore ISI HealthCONx Conference |
| 29/11/2023 01:00 am | Piper Sandler Healthcare Conference |
| 13/11/2023 06:30 pm | Q3 2023 Earnings Release |
| 09/11/2023 02:30 am | UBS BioPharma Conference |
| 08/11/2023 01:40 am | Guggenheim Healthcare Talks I&I Conference |
| 04/11/2023 09:30 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number:704 |
| 03/11/2023 10:30 pm | FLX475 Phase 2 Trial Results Call |
| 03/11/2023 09:30 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number:629-C |
| 26/09/2023 11:05 pm | Cantor Global Healthcare Conference |
| 20/09/2023 01:15 am | Stifel Immunology & Inflammation Virtual Summit |
| 11/09/2023 11:30 pm | H.C. Wainwright Global Investment Conference |
| 06/09/2023 05:30 pm | Wells Fargo Healthcare Conference |
| 11/08/2023 05:30 pm | Q2 2023 Earnings Release |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 5,04 4,59 9.84% | 3,81 3,84 -0.68% | 1,53 1,62 -5.98% | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -42,3 -50,4 16.11% | -52,1 -55,1 5.52% | -68,2 -69,6 2.03% | -84,7 -84,1 -0.82% | -126 -127 0.63% | -132 |
|
EBIT Million USD | Released Forecast Spread | -43,6 -47,0 7.22% | -53,2 -55,1 3.46% | -69,2 -74,4 6.94% | -85,8 -84,6 -1.4% | -127 -127 -0.23% | -131 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -42,3 -42,1 -0.46% | -51,9 -54,1 4.09% | -69,2 -75,1 7.88% | -83,8 -84,1 0.34% | -117 -120 2.34% | -124 |
|
Net income Million USD | Released Forecast Spread | -43,0 -42,1 -2.03% | -52,9 -54,6 3.09% | -69,2 -73,4 5.71% | -83,8 -84,1 0.29% | -117 -119 2.02% | -129 |
|
EPS USD | Released Forecast Spread | -9,89 -4,83 -104.69% | -2,19 -2,24 2.33% | -2,53 -2,65 4.67% | -2,58 -2,60 0.83% | -3,05 -3,11 1.98% | -3,12 |
| Announcement Date | 30/03/20 | 11/03/21 | 10/03/22 | 14/03/23 | 07/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,76 0,70 8.76% | 0,64 0,31 108.12% | 0,89 0,31 187.66% | 0,00 0,29 - | 0,00 0,13 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -17,8 -22,0 19.08% | -20,5 -21,0 2.3% | -18,6 -25,0 25.46% | -21,4 -23,0 6.88% | -24,2 -25,0 3.28% | -31,3 -26,0 -20.24% | -28,1 -32,0 12.2% | -33,6 -29,0 -15.84% | -32,9 -35,0 6.02% | |||||
|
EBIT Million USD | Released Forecast Spread | -18,0 -20,9 13.7% | -20,8 -20,4 -1.67% | -18,9 -22,4 15.64% | -21,7 -22,0 1.33% | -24,4 -23,3 -4.87% | -31,6 -25,7 -22.77% | -28,4 -31,3 9.26% | -33,9 -30,1 -12.7% | -33,2 -34,3 3.22% | -32,8 | -32,6 | -32,5 | -33,4 | -29,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -17,9 -21,1 15.16% | -20,5 -20,7 1.24% | -19,2 -22,6 15.03% | -21,2 -22,3 4.64% | -23,0 -23,2 1.21% | -29,3 -25,6 -14.25% | -25,3 -30,7 17.61% | -31,4 -29,0 -8.18% | -30,9 -33,2 6.92% | -30,5 | -30,6 | -30,6 | -32,2 | -29,2 |
|
Net income Million USD | Released Forecast Spread | -17,9 -19,8 9.54% | -20,5 -19,9 -2.98% | -19,2 -22,5 14.86% | -21,2 -21,6 1.68% | -23,0 -23,1 0.77% | -29,3 -24,6 -18.97% | -25,3 -30,4 16.8% | -31,4 -28,9 -8.55% | -30,9 -32,8 5.87% | -30,6 | -31,2 | -31,6 | -33,6 | -29,2 |
|
EPS USD | Released Forecast Spread | -0,61 -0,67 8.39% | -0,69 -0,68 -1.57% | -0,62 -0,74 16.1% | -0,63 -0,67 6.1% | -0,64 -0,66 3.59% | -0,76 -0,68 -11.8% | -0,66 -0,80 17.04% | -0,82 -0,75 -8.91% | -0,81 -0,86 5.5% | -0,80 | -0,81 | -0,77 | -0,73 | -0,76 |
| Announcement Date | 10/03/22 | 11/05/22 | 11/08/22 | 10/11/22 | 14/03/23 | 11/05/23 | 11/08/23 | 13/11/23 | 07/03/24 | - | - | - | - | - |
More events
Past sector events for RAPT Therapeutics, Inc.
| 03/05/2024 04:30 pm | GH RESEARCH PLC: Q1 2024 Earnings Release |
| 03/05/2024 01:35 am | KURA ONCOLOGY, INC.: Q1 2024 Earnings Release |
| 03/05/2024 01:35 am | ZYMEWORKS INC.: Q1 2024 Earnings Release |
| 03/05/2024 01:32 am | ARDELYX, INC.: Q1 2024 Earnings Release |
| 03/05/2024 01:31 am | LONGBOARD PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 03/05/2024 01:31 am | ASCENDIS PHARMA A/S: Q1 2024 Earnings Release |
| 03/05/2024 01:30 am | ULTRAGENYX PHARMACEUTICAL INC.: Q1 2024 Earnings Release |
| 02/05/2024 08:30 pm | GENMAB A/S: Q1 2024 Earnings Release |
| 02/05/2024 04:30 pm | GERON CORPORATION: Q1 2024 Earnings Release |
| 02/05/2024 04:30 pm | AGIOS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- RAPT Stock
- Calendar RAPT Therapeutics, Inc.
